Copyright (c) 2026 Fatima Khatoon, Syed Mohammed Kazim, Mohammed Abdul Aleem, Ayesha Rahamath, Ayesha Siddiqua, Firdous Fatima, Syeda Noor-Ain
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
A Prospective Clinical Evaluation of Olanzapine-Based Antiemetic Regimen in Chemotherapy-Induced Nausea and Vomiting
Corresponding Author(s) : Fatima Khatoon
International Journal of Allied Medical Sciences and Clinical Research,
Vol. 14 No. 2 (2026): 2026 Volume -14 - Issue 2
Abstract
Aim: A Prospective Clinical Evaluation of Olanzapine-Based Antiemetic Regimen in Chemotherapy-Induced Nausea and Vomiting
Background: Chemotherapy-induced nausea and vomiting (CINV) is a debilitating side effect of cancer treatment that significantly impairs patient quality of life. While conventional regimens (5-HT3 antagonists and corticosteroids) are available, many patients still experience inadequate control, particularly in the delayed phase. Olanzapine, an atypical antipsychotic, has emerged as a promising agent due to its broad receptor-blocking activity.[1][2][9][3]
Objective: To prospectively evaluate the clinical efficacy and safety of olanzapine in preventing and managing CINV in patients receiving highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC).[3]
Methodology: A prospective observational study was conducted over six months in the Medical Oncology department of a tertiary care hospital. The study included 50 adult cancer patients receiving HEC or MEC. Olanzapine (5mg or 10mg) was administered as part of the antiemetic regimen. Outcomes were recorded using the MASCC antiemetics tool and Visual Analogue Scale (VAS).[6]
Results:
- Demographics: 70% of participants were female, and 30% were male, with the majority aged between 40–65 years.
- Common Diagnoses: Breast cancer was the most frequent diagnosis, followed by lung and ovarian cancers.
- Efficacy: A complete response (no vomiting and no rescue medication) was achieved in 68% of patients. Acute and delayed phase control rates were 74% and 61%, respectively.
- Safety: The regimen was generally well-tolerated. The most common adverse effect was mild sedation (16%), followed by dizziness.[3][2][11]
Conclusion: Olanzapine-based therapy provides superior control for both acute and delayed CINV, particularly in HEC settings. Its clinical value is underscored by its cost-effectiveness and ability to reduce CINV-related morbidity.[2][3][10]